Skip to main content

Macrogenics Inc 8-K, filed Nov 13, 2026

Macrogenics Inc (MGNX)

8-K 2026-11-13 For: 2026-11-13
View Original
Added on November 13, 2026

About this 8-K

Macrogenics Inc filed this 8-K on November 13, 2026.

MacroGenics’ updated presentation reports MGC026 best overall response rate of 27% in late-line SCCHN, with 64% disease control rate, and $288M in cash and marketable securities supporting cash runway guidance through 2028. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits